pipelin compani focu near-term execut
messag report earn larg line
investor expect compani larg reiter guidanc near-term mileston
includ bla submiss margetuximab breast cancer full dataset
interim sabc data readout flotetuzumab clinic trial initi
across pipelin push guidanc bispecif data
updat
intend file bla margetuximab base sophia trial result
recal sophia interim analysi mix given statist mo miss
intent-to-treat well allel popul well surviv trend
favor margetuximab except allele-neg group link compani intend
continu bla file though call mention would surpris
fda request advisori committe compani read full dataset
interim upcom san antonio breast cancer symposium sabc expect
read final os analysi event
guidanc updat bispecif data read
previous trial enrol patient across tumor type earli
evid activ naiv pretreat patient accord management
intend delay readout order allow addit time patient obtain either
first confirmatori scan
modul phase ii mahogani trial evalu margetuximab gastric cancer
dose first patient octob modul start recal mahogani
modul consist singl arm cohort margetuximab potenti
acceler approv base orr endpoint patient compani
hope surpass orr achiev trastuzumab chemo phase
toga trial phase ii portion modul modul four arm
compar margetuximab chemo checkpoint inhibitor either
bispecif standard care trastuzumab chemo
enoblituzumab initi potenti registration-en phase ii/iii trial front-
line head neck cancer shortli recal enoblituzumab trial similarli design
mahogani phase ii portion evalu keytruda mab
chemo enoblituzumab without chemo provid go/
no-go phase registr phase aim evalu enoblituzumab
without chemo head-to-head keytruda chemo
flotetuzumab read updat data focu primari refractori
early-relaps aml patient combin studi inhibitor
cr rate among evalu primari refractori earli relaps aml
well patient subsequ underw allogen stem cell transplant data
updat releas includ cr rate among
continu remain neutral rate pleas see initi sinc believ
margetuximab commerci potenti breast gastric cancer modest
given competitor antibody-drug conjug dsnky/azn
tucatinib see read significantli compel data similar
patient popul similarli think bispecif flotetuzumab may enter
moder size market aml could potenti becom crowd given sever
competitor bispecif antibody-drug conjug target cytotoxin
page analyst certif import disclosur
car-t therapi develop agent enoblituzumab view
modest singl agent activ contribut toward combin
unclear poc readout given orr post-checkpoint inhibitor patient
updat estim account result end quarter
cash equival expect suffici runway
page analyst certif import disclosur
valuat risk
valu use discount cash flow analysi use
wacc consist clinical-stag biotech compani cover
proof-of-concept data well termin growth rate downsid risk includ
 regulatori commerci setback potenti emerg new competitor
lower product sale expect upsid risk includ higher product sale
expect pipelin success beyond alreadi account forecast
potenti acquisit premium current valuat
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
